Jiangsu Nhwa Pharmaceutical Co., LTD

Equities

002262

CNE100000CG8

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-14 pm EDT 5-day change 1st Jan Change
23.28 CNY +3.19% Intraday chart for Jiangsu Nhwa Pharmaceutical Co., LTD +6.94% -14.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nhwa Pharma Gets Nod to Test NH103 Oxalate Tablets MT
Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Profit Distribution for 2023 CI
Nhwa Pharmaceutical's 2023 Profit Climbs 15% as Revenue Rises 17% MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Exchange-Traded Funds Higher, Equity Futures Lower Pre-Bell Monday Ahead of Data-Packed Week MT
Teva Pharmaceutical Investments Singapore Pte Ltd. and Jiangsu Nhwa Pharmaceutical Co., LTD Forge Strategic Partnership to Promote Patient Access to Austedo® in China CI
Nhwa Pharmaceutical Gets Green Light from US FDA After Addressing API Deficiencies MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Yihua M-Health Technology Co., Ltd. announced that it expects to receive CNY 30 million in funding from Jiangsu Nhwa Pharmaceutical Co., LTD CI
Jiangsu Nhwa Pharmaceutical Co., LTD(XSEC:002262) added to FTSE All-World Index CI
Jiangsu Nhwa Pharma’s H1 Profit Jumps 21.7% as Revenue Rises 20% MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wang Zeyu cancelled the acquisition of 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD. CI
Expected House Vote on Debt Ceiling Deal Weighs on Sentiment, Pushing US Equity Futures Lower MT
Trevena Receives $3 Million Milestone Payment From Partner Jiangsu Nhwa Pharmaceutical MT
Top Premarket Gainers MT
Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Formal Approval from the National Medical Products Administration for OLINVYK CI
Jiangsu Nhwa Pharmaceutical Co., Ltd Approves Cash Dividend for 2022, Payable on 28 April 2023 CI
Jiangsu Nhwa Pharma’s Q1 Profit Jumps 20.5% as Revenue Rises 19%; Shares Jump 5% MT
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Jiangsu Nhwa Pharmaceutical Co., LTD Proposes Final Cash Dividend for 2022 CI
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Mr Wang Zeyu agreed to acquire 13% stake in Jiangsu Farever Pharma Co., Ltd. from Jiangsu Nhwa Pharmaceutical Co., LTD for CNY11.4673 million. CI
Jiangsu Nhwa Pharmaceutical Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Jiangsu Nhwa Pharmaceutical Co., LTD Proposes Final Cash Dividend on A Shares for the Year 2021, Payable on May 13, 2022 CI
Chart Jiangsu Nhwa Pharmaceutical Co., LTD
More charts
Jiangsu Nhwa Pharmaceutical Co., LTD is a China-based company principally engaged in the production and sales of pharmaceutical preparations. The Company offers its pharmaceutical products under four categories, which consist of anesthetic medicines, including midazolam injections and etomidate fat emulsion pharmaceutical preparations injections; psychiatric medicines, including risperidone tablets and others; neurological medicines, including gabapentin capsules and others; bulk drugs, including fenofibrate and miconazole nitrate. The Company is also engaged in the pharmaceuticals trading business. Through its subsidiaries, the Company is also engaged in the Internet medical businesses. The Company distributes its products within domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
23.28 CNY
Average target price
32.7 CNY
Spread / Average Target
+40.47%
Consensus
  1. Stock Market
  2. Equities
  3. 002262 Stock
  4. News Jiangsu Nhwa Pharmaceutical Co., LTD
  5. Jiangsu Nhwa Pharma Signs Nearly $18 Million Deal to License Lundbeck’s Schizophrenia Drug